Skip to main content
Equibles
TRDA logo

TRDA · Entrada Therapeutics, Inc.

Track TRDA — free

Use TRDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.80 +0.38 (+5.92%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$248.42M
Shares
38.94M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.80 Open$6.49 Day$6.29–6.81 52W close$5.06–16.03 Avg vol 30d320K Short int2.3M · 6.0% float · 10.7d Short vol34% Last earningsMay 7, 2026 DataOct 2021–Sep 2026 Filing10-Q · Aug 5

Up next

Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.69M
Trailing 12 months
Net income (TTM)
−$165.78M
Trailing 12 months
Revenue growth YoY
-53.9%
Year over year
Operating margin
-3,767.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+23.0%
Trailing year
Short interest
6.0%
Latest settlement · 10.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −29%
below
Price vs 50-day avg −3%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 16%
mid-range
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −40%
trailing
YTD return −34%
this year
Relative strength −58%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +26 funds added
Insider flow Distributing
Net -$10.3M over 90 days · 100% sells
Short interest Falling
6.02% of float · ▼ -0.9% MoM · 10.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
128 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Poor
Revenue growth −88%
Y/Y
EPS growth −307%
Y/Y
Free cash flow $-129.6M
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −65%
past year
ATR 7.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−29% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +26 funds added
Insider flow Distributing
Net -$10.3M over 90 days · 100% sells
Short interest Falling
6.02% of float · ▼ -0.9% MoM · 10.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
128 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $7 · 16% Range high $16
vs 200-day avg -29% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TRDA
Entrada Therapeutics, Inc.
this stock
$248.42M -33.9% -87.9% — 6.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
128
% held
74.7%
Net QoQ
+3.6M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
141
View
Short & Settlement
Short Interest Falling
Shares short
2.3M
Days to cover
10.7d
Change
-21.2K sh
View
Short Volume
Short vol %
34%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
2.0K
Value
$14.5K
As of
Aug 4, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$10.3M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$25.4M
Net income (FY)
$-143.8M
EPS diluted
$-3.47
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
10
View
Proposed Sales
Value
$2.2M
Shares
331.2K
Filed
Jul 30, 2026
View
Exempt Offerings
Offering
$116.2M
Filed
Apr 13, 2021
View
Earnings & Events
Earnings Calls
Last call
May 7, 2026
View

Performance

5D 20D 120D MTD YTD
TRDA -5.2% -8.7% -39.9% -3.6% -33.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.0% -7.0% -57.7% -3.2% -45.9%
Key facts CIK 1689375 CUSIP 29384C108 13F (30d) 75 filings 75 filers Visit website Investor relations